Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.70 +1.2%	$1.48	$1.05 ▼ $5.17	$181.91M	0.38	1.24 million shs	441,182 shs
BDTX Black Diamond Therapeutics	$2.97 -4.8%	$2.52	$1.20 ▼ $6.75	$177.41M	2.71	1.21 million shs	899,836 shs
MRSN Mersana Therapeutics	$0.31 -4.4%	$8.58	$0.26 ▼ $2.83	$40.14M	0.79	3.47 million shs	5.63 million shs
VYGR Voyager Therapeutics	$3.24 -2.1%	$3.18	$2.64 ▼ $9.55	$183.16M	0.85	610,688 shs	581,579 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+1.19%	+5.59%	+4.29%	+26.87%	+23.19%
BDTX Black Diamond Therapeutics	-4.81%	-5.11%	+14.67%	+86.79%	-51.15%
MRSN Mersana Therapeutics	-96.18%	-96.51%	-96.48%	-96.61%	-99.42%
VYGR Voyager Therapeutics	-2.11%	0.00%	+10.20%	-6.63%	-63.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.3901 of 5 stars	3.6	1.0	0.0	3.3	1.7	0.6
BDTX Black Diamond Therapeutics	2.9703 of 5 stars	3.5	3.0	0.0	3.3	1.7	0.6
MRSN Mersana Therapeutics	4.0054 of 5 stars	3.5	3.0	4.1	1.7	2.5	0.0
VYGR Voyager Therapeutics	3.8683 of 5 stars	3.6	2.0	4.6	1.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	412.61% Upside
BDTX Black Diamond Therapeutics	3.00	Buy	$12.80	330.98% Upside
MRSN Mersana Therapeutics	3.00	Buy	$130.00	42,107.79% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	313.27% Upside

Current Analyst Ratings Breakdown

Latest MRSN, BDTX, VYGR, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$225.00 ➝ $250.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$75.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00

(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.83	N/A	N/A	$1.44 per share	1.18
BDTX Black Diamond Therapeutics	$70M	2.41	N/A	N/A	$1.47 per share	2.02
MRSN Mersana Therapeutics	$40.50M	0.95	N/A	N/A	($0.08) per share	-3.85
VYGR Voyager Therapeutics	$80M	2.24	N/A	N/A	$5.49 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
BDTX Black Diamond Therapeutics	-$69.68M	$0.06	49.50	N/A	N/A	N/A	4.70%	3.47%	8/5/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)

Latest MRSN, BDTX, VYGR, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MRSN Mersana Therapeutics	-$0.18	N/A	N/A	N/A	$6.06 million	N/A
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
8/5/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	N/A	N/A	N/A	$9.50 million	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$5.25	-$4.75	+$0.50	-$0.19	$6.05 million	$2.75 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
BDTX Black Diamond Therapeutics	N/A	9.24	9.24
MRSN Mersana Therapeutics	N/A	1.83	1.83
VYGR Voyager Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
BDTX Black Diamond Therapeutics	95.47%
MRSN Mersana Therapeutics	93.92%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
BDTX Black Diamond Therapeutics	5.97%
MRSN Mersana Therapeutics	13.00%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	53.47 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	51.80 million	Optionable

MRSN, BDTX, VYGR, and ACRS Headlines

Recent News About These Companies

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Head to Head Survey: Acumen Pharmaceuticals (NASDAQ:ABOS) & Voyager Therapeutics (NASDAQ:VYGR)

July 20, 2025 | americanbankingnews.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

Uranus Heat Readings Contradict 40-Year-Old Voyager 2 Results

July 16, 2025 | msn.com

Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16, 2025 | finanznachrichten.de

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16, 2025 | globenewswire.com

Moon + Bird acquires Alastair Chisholm's book about NASA’s Voyager 1

July 15, 2025 | thebookseller.comT

Embark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and More

July 14, 2025 | prestigeonline.comP

Voyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star Trek

July 14, 2025 | fandomwire.comF

UK awards AirTanker network node upgrade for Voyager

July 11, 2025 | janes.comJ

Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology

July 10, 2025 | msn.com

RNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'

July 7, 2025 | itv.comI

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager

July 6, 2025 | cruiseindustrynews.comC

With Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-Wallets

July 5, 2025 | travelmole.comT

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

July 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, BDTX, VYGR, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.70 +0.02 (+1.19%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$1.82 +0.12 (+7.06%)

As of 07/25/2025 07:59 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Black Diamond Therapeutics NASDAQ:BDTX

$2.97 -0.15 (-4.81%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$3.04 +0.07 (+2.39%)

As of 07/25/2025 07:56 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics NASDAQ:MRSN

$0.31 -0.01 (-4.38%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$0.31 +0.01 (+1.95%)

As of 07/25/2025 07:43 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics NASDAQ:VYGR

$3.24 -0.07 (-2.11%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$3.26 +0.02 (+0.77%)

As of 07/25/2025 07:27 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time